RIBOMIC, Inc. engages in the research and development of molecular targeted drugs using Ribonucleic Acid (RNA) aptamers for use in therapeutic fields. It utilizes the Ribomic Aptamer Therapeutics (RiboART) system to discover new drugs that are applicable to target proteins. The company was founded by Yoshikazu Nakamura on August 1, 2003 and is headquartered in Tokyo, Japan.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company